Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc., originally spun out of Hewlett-Packard in 1999, has evolved into a leading firm in the life sciences and diagnostics sector. The company specializes in creating advanced measurement technologies that serve a vast range of customers across various industries.
The company's core business revolves around three main segments: life science and applied tools, cross lab (which includes consumables and services related to life sciences and applied tools), and diagnostics and genomics. These segments collectively cater to a broad spectrum of markets, including biopharmaceuticals, chemicals, advanced materials, clinical labs, environmental testing, forensics, food safety, academic research, and government-related organizations.
Agilent's geographical reach is extensive, with significant operations in the U.S. and China. The company is committed to addressing global trends impacting human health and the environment and continuously anticipates future scientific needs.
Agilent provides comprehensive laboratory solutions that enhance the efficiency of laboratories, from sample preparation to data interpretation and management. Their instruments, software, services, and consumables are designed to meet the most complex laboratory demands, empowering scientists and researchers worldwide to make impactful discoveries and improvements in various fields.
Recent achievements include advancements in biopharmaceutical technology, collaborations with leading research institutions, and the launch of state-of-the-art diagnostic tools. The company also emphasizes sustainable practices and innovations aimed at improving human health and environmental outcomes.
Agilent Technologies Inc. (NYSE: A) will announce its fourth-quarter fiscal year 2021 financial results post market close on November 22, 2021. A live webcast of the investor conference call will take place at 1:30 p.m. Pacific Time on the same day. In fiscal year 2020, the company reported a revenue of $5.34 billion and employs 16,400 people globally. The webcast will be available on their website for 90 days after the event.
Agilent Technologies (NYSE: A) has achieved the highest sponsorship level with My Green Lab as the first to do so. This partnership enhances Agilent's commitment to sustainability in scientific research, emphasizing green purchasing practices. Since its inception in 2013, My Green Lab focuses on improving environmental responsibility in labs. Agilent has received My Green Lab's ACT labels for major product lines and sponsors the certification program recognized in the UNFCCC's 2030 Breakthroughs. Agilent is consistently ranked among the world's most sustainable corporations.
Agilent Technologies Inc. (NYSE: A) has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx, intended to assist in first-line treatment decisions for adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. Gastric and esophageal cancers are significant global health issues, with over 1.6 million cases reported in 2020. The PD-L1 IHC 28-8 pharmDx enhances treatment confidence when used with OPDIVO® (nivolumab), demonstrating superior survival rates compared to chemotherapy alone.
Agilent Technologies (NYSE: A) announced FDA approval for its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) as a diagnostic tool for early breast cancer (EBC) patients at high risk of disease recurrence. This assay, developed in partnership with Eli Lilly, is the first to be approved for use with the drug Verzenio (abemaciclib). The approval is critical for better recurrence risk assessment, complementing traditional staging methods. This move positions Agilent as a key player in the diagnostic assay market, enhancing treatment decision-making for high-risk EBC patients.
Agilent Technologies (NYSE: A) awarded the Agilent Thought Leader Award to Professor Bernhard Lendl from TU Wien for his pioneering work in vibrational spectroscopy. This award aims to enhance infrared quantum cascade laser applications in biopharma, specifically improving analysis methods for biomolecules in challenging aqueous environments. The recognition highlights the importance of advancing analytical tools for rapid assessment of therapeutic proteins and viral vectors, addressing critical bottlenecks in biopharmaceutical workflows.
Agilent Technologies, Inc. (NYSE: A) has appointed Dr. Mikael Dolsten, Pfizer's Chief Scientific Officer, to its board of directors effective September 21, 2021. Dr. Dolsten brings over 30 years of pharmaceutical expertise, having led numerous drug candidates into human studies and contributing to the development of over 30 approved drugs and vaccines. His leadership in small-molecule medicines and biotherapeutics is expected to enhance Agilent's strategic initiatives. This appointment is seen as a significant addition to the board, aiming to strengthen Agilent's capabilities in life sciences and diagnostics.
Agilent Technologies, Inc. (NYSE: A) announced a quarterly dividend of 19.4 cents per share, payable on October 27, 2021, to shareholders on record as of October 5, 2021. The decision on future dividends will depend on the board's approval. For fiscal year 2020, Agilent generated $5.34 billion in revenue and employs approximately 16,400 people worldwide. This announcement reflects the company's commitment to returning value to its shareholders while navigating industry uncertainties.
Agilent Technologies (NYSE: A) has awarded the prestigious Agilent Thought Leader Award to Dr. David R. Liu, a notable researcher in genome editing. This recognition aims to support Dr. Liu's groundbreaking work on CRISPR applications and genetic diseases. Agilent's funding will enhance research into molecular editing tools such as base and prime editing, which target genetic disorders. Dr. Liu expressed gratitude for the support, while Agilent emphasized its commitment to advancing CRISPR methodologies and genomics profiling tools, contributing to significant scientific advancements.
Agilent Technologies (NYSE: A) has signed a worldwide distribution agreement with Visiopharm to co-market AI-driven precision pathology software alongside Agilent's automated staining solutions. This collaboration, initially focused on Europe, marks Agilent's entry into the digital pathology market, which is projected to double in adoption by 2030. The COVID-19 pandemic has accelerated this trend as pathologists increasingly use remote reporting. The partnership aims to enhance diagnostic accuracy and workflow efficiency for pathologists, contributing to improved patient care.
FAQ
What is the current stock price of Agilent Technologies (A)?
What is the market cap of Agilent Technologies (A)?
What does Agilent Technologies Inc. specialize in?
When was Agilent Technologies Inc. founded?
What are the main business segments of Agilent Technologies Inc.?
Which industries does Agilent Technologies Inc. serve?
Where are Agilent Technologies Inc.'s main operations located?
What recent achievements has Agilent Technologies Inc. made?
How does Agilent Technologies Inc. contribute to laboratory efficiency?
What sustainable practices does Agilent Technologies Inc. emphasize?
Why do scientists and researchers trust Agilent Technologies Inc.?
What kind of global issues does Agilent Technologies Inc. address?
